Sponsor:
David Marcinek
Code:
NCT07275424
Conditions
Aging, Healthy
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Accepted
Interventions
Elamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
Brief summary:
Conditions
Aging, Healthy
Study ID
NCT07275424
Start date
Nov 26, 2025
Status verified date
Dec, 2025
Completion date
Apr 15, 2026
Anticipated
Primary completion date
Mar 15, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Accepted
Enrollment
30 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
other: Safety and tolerability of daily subcutaneous injection of elamipretide
Interventions
Elamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
Primary outcome measure
Central contacts
Locations
University of Washington
Recruiting
Seattle, Washington, United States, 98109
Contacts
Sponsor
David Marcinek
Last update posted
Dec 10, 2025
Last verified
Dec, 2025
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by David Marcinek on 2025-12-10.